159 results about "Tumor marker" patented technology

The invention relates to the technical field of spectral analysis and biomedical detection, and discloses an SERS (Surface Enhanced Raman Scattering) spectrum quantitative detection method and system based on interpretable stacked ensemble learning. The method comprises the following steps: acquiring SERS spectral data of serum tumor marker standard substances with different concentration gradients; performing baseline correction and normalization preprocessing on the data, performing sparse feature selection by using an LASSO algorithm, and screening out key spectral features to construct a sample data set; constructing an interpretable stacking integration model, wherein the model adopts a base learner layer and a meta learner layer; training the model by using the training set, optimizing model hyper-parameters by using a cross validation strategy, and establishing a mapping relationship between spectral features and tumor marker concentrations; and collecting SERS spectral data of a to-be-detected serum sample, extracting key spectral features, inputting the key spectral features into the trained interpretable stacked integrated model, and outputting a concentration predicted value of the tumor marker in the to-be-detected serum sample. The method has the advantages of high precision, universality and molecular level interpretability.

The invention relates to the technical field of tumor markers, in particular to a pancreatic cancer early screening marker combination based on blood protein and application of the pancreatic cancer early screening marker combination. Through proteomics analysis and bioinformatics screening, 12 kinds of proteins such as NME3, HPGDS, CEACAM5, TNFSF12, SCG3, VTCN1, GFRA1, KRT19, TMPRSS12, NELL2, KAZALD and MMP12 are determined to serve as the potential early screening markers of the pancreatic cancer. Researches show that the combination of the proteins can effectively distinguish pancreatic cancer patients from non-pancreatic cancer patients, and has good sensitivity and specificity. A screening model constructed based on the protein combination can be applied to auxiliary diagnosis, risk assessment and population screening of pancreatic cancer, and has important clinical transformation value.

Methods for detecting a tumor using a sample in which tumor DNA fragments are present only in a very low concentration, beyond the statistical limit of detection, where methods include: obtaining sequence data for tumor nucleic acid from a tumor from a subject and analyzing the sequence data to identify a plurality of tumor-specific variants that are in the tumor nucleic acid and that are not in non-tumor nucleic acid of the subject; selecting a marker variant that appears duplicated in tumor nucleic acid (compared to non-tumor nucleic acid) a greater number of times than other ones of the tumor variants; performing an assay to detect the marker variant in a sample from the subject; and reporting the presence of the tumor in the subject when the assay is positive for the marker variant in the sample.

The invention discloses an immune quantitative detection device for tumor markers, relates to the technical field of medical detection, and aims to solve the problems of complicated operation, long detection period and poor portability in immune quantitative detection of tumor markers in the prior art. Comprising a shell, a disposable detection card, a multi-channel micro-fluidic chip, a high-sensitivity sensing system, a micro magnetic control incubation module, an AI auxiliary image recognition system and a wireless transmission module, the disposable detection card is used for accommodating the multi-channel micro-fluidic chip and a reaction reagent, and the multi-channel micro-fluidic chip is respectively aligned with the high-sensitivity sensing system and the micro magnetic control incubation module; the high-sensitivity sensing system is composed of a surface plasma resonance sensor and a quantum dot fluorescence labeling module, and the surface of a sensing chip of the surface plasma resonance sensor is modified with a tumor marker specific capture antibody. The method has the advantages of convenient detection and high efficiency and precision.

The invention discloses a big data-based digestive system department prediction analysis system. The system comprises a data acquisition module, a knowledge graph fusion module, a disease course evolution prediction module and an intelligent diagnosis and treatment decision module. The invention relates to the technical field of medical health information, in particular to a big-data-based predictive analysis system for the department of gastroenterology. According to the scheme, a physiological signal is reconstructed by using a multi-scale mask auto-encoder, and the signal and a text are aligned; mapping knowledge graph regularization is introduced, the joint code is mapped to a digestive system knowledge graph space, and medical semantic representation is obtained; constructing a time sequence attenuation dynamic graph through the dynamic memory graph, and adding graph convolution gating; an embedded differential equation module simulates inflammation and tumor marker evolution to realize accurate prediction; patient state vectors are constructed based on multi-modal coding, medicines are rapidly selected by using a scoring function, a treatment process is modeled as a Markov decision, and a strategy network, a value network and PPO optimization are combined to realize balance of curative effect and income.

This invention relates to aggregation-induced emission probes with specific responses to tumor markers and their applications, belonging to the field of biochemistry. This invention utilizes molecular structure modulation to prepare a series of molecules possessing large Stokes shifts, resistance to photobleaching, near-infrared II (NIR-II) emission, and aggregation-induced emission properties. Different self-eliminating groups are attached to the dimethylamino group of the molecule via quaternization or to the pyridine group via pyridinium salting. By controlling the structure of these self-eliminating groups, activatable luminescent probes responding to different tumor markers can be constructed. These probes integrate deep NIR-II imaging, aggregation-point luminescence, large Stokes shifts, and marker-specific responses, providing a new approach for precise imaging diagnosis of tumors.

The invention relates to the technical field of biology, in particular to an eccDNA marker and application thereof in prognosis prediction of colorectal cancer. According to the present invention, the chromosome outer circular DNA is adopted as the colorectal cancer prognosis prediction marker, and the colorectal cancer prognosis prediction marker is significantly superior to the common tumor marker when the colorectal cancer prognosis prediction marker is used; a colorectal cancer prognosis prediction model constructed by adopting the eccDNA marker provided by the invention is high in diagnosis accuracy, high in sensitivity and strong in specificity, and has excellent application potential in clinical risk stratification.

This invention relates to the field of biomedical technology, providing the application of glycoprotein tumor biomarkers in the preparation of cancer diagnostic reagents. The glycoprotein tumor biomarker is a CLU_N_291_HexNAc(4)Hex(5) site-specific glycosylation modification. This invention utilizes CLU_N_291_HexNAc(4)Hex(5) site-specific glycosylation modification as a pan-cancer biomarker, combining it with existing conventional tumor markers (CEA, CA19-9, CA50, CA242, CA72-4, CA125, CA15-3, AFP, SCC, CYFRA21-1, PROGRP, NSE, HE-4, or PSA) for early cancer screening, assessment, diagnosis, postoperative monitoring, and / or prognostic analysis, particularly for the diagnosis of pancreatic cancer, cholangiocarcinoma, gastric cancer, lung cancer, breast cancer, or ovarian cancer.

The invention discloses a tumor specific signal analysis device and equipment for uncertain pulmonary nodules and a storage medium, and relates to the technical field of electrical digital data processing.The device constructs a LungTCR database containing lung cancer tissue enrichment type and blood enrichment type CDR3 sequences through TCR beta chain sequencing and IMGT database comparison, and the LungTCR database is used for analyzing the lung cancer tissue enrichment type and blood enrichment type CDR3 sequences. A basis is provided for tumor specific signal recognition; a Needleman-Wunsch algorithm and an editing distance threshold value are adopted for screening, so that high-precision sequence matching is realized; through quantification of lung cancer tissue scores, blood scores and mutation specificity scores, a TCR feature group with biological significance is formed; and finally, the TCRnodseek plus model trained by clinical and image features is combined, a reliable malignant probability prediction value can be output, the model AUC can reach 0.90 or above, and the model is obviously superior to traditional imaging diagnosis and tumor markers.

The invention belongs to the technical field of medical detection, and particularly relates to an electrochemical device for detecting tumor cells in blood and a preparation method of the electrochemical device. The electrochemical device comprises a biocompatible flexible substrate, a side gate electrode, a source electrode, a drain electrode, an insulating film, a hydrophilic semiconductor and a ligand for capturing a tumor marker, the hydrophilic semiconductor is arranged between the source electrode and the drain electrode, and the biological ligand for capturing the tumor cell marker is arranged on the side gate electrode; the side gate electrode is used for generating induced voltage when a tumor in a blood vessel is captured, so that induced current is generated between the source electrode and the drain electrode; the insulating film is deposited on the part outside the channel and the side gate electrode, so that crosstalk between adjacent electrodes is prevented. The invention also discloses a manufacturing method and a testing method of the electrochemical device. The electrochemical device can realize minimally invasive and real-time detection, and is simple in structure, low in power consumption, high in stability, small in detection wound and high in detection speed.

The invention relates to the technical field of biomedical detection, in particular to a multi-dimensional tumor marker joint detection device and a using method thereof.The device comprises a sample processing module, a sequencing module, a marker extraction module, a feature fusion and detection module and a result output module, and 6 types of markers such as chromosome copy variation, microsatellite instability and the like are extracted respectively. The method comprises the following steps: collecting a body fluid sample to extract cfDNA, directly constructing a library without special treatment, obtaining effective data through whole genome sequencing, synchronously extracting six types of markers through each module of the device, optimizing an algorithm to adapt to low-depth data, inputting an integrated learning model to output a risk score, and finally outputting related information by a result output module. The method does not need special experimental treatment, realizes low-cost and high-accuracy joint detection, and meets the clinical large-scale screening requirements.

The present application relates to the field of tumor markers, in particular to a fascin acetylation modification which can be used as a tumor diagnosis and prognosis analysis marker, a detection reagent and application thereof. The present application is directed to the fact that acetylation modification at K41 site of fascin significantly inhibits the cancer-promoting activity of fascin protein, and in esophageal cancer tissue, the proportion of fascin with acetylation modification at K41 site is significantly lower than that of wild-type fascin in para-cancerous tissue. Based on the acetylation at K41 site of fascin, a specific antibody for acetylation at K41 site of fascin is developed, so as to conduct clinical application research on acetylation at K41 site of fascin, and establish an esophageal cancer prognosis analysis model and targeted treatment.

The application provides a DNA sensor based on gold nanoparticles (AuNPs) for visual detection of miRNA-10b. The sensor is obtained by coupling AuNPs-S1 through mercapto between gold nanoparticles (AuNPs) and probe S1; and coupling AuNPs-S2 through mercapto between gold nanoparticles (AuNPs) and probe S2. The combination of the probe and the gold nanoparticles is more firm due to mercapto modification, so that the stability and detection repeatability of the DNA sensor are improved. The aggregation of AuNPs is triggered by hybridization between the target miRNA-10b and the probe, the transition of AuNPs from dispersion to aggregation in the buffer solution is regulated, and the color change from red to blue is visible to the naked eye, so that the rapid and visual detection of the tumor marker miRNA-10b is realized. The linear range is 10 pM-200 nM, and the sensor has excellent stability in serum environments (1%, 10%) and enzymatic environments (5 U / mL DNase and 2 U / mL DNase), and high selectivity. An efficient tool is provided for cancer diagnosis.

This application relates to the field of biotechnology, specifically disclosing the application of immune cell subsets in the preparation of detection products for assessing the efficacy of neoadjuvant therapy and the risk of recurrence and metastasis in breast cancer. The detection method described in this application is non-invasive and convenient, requiring only peripheral blood, and is easy to repeat sampling and dynamic monitoring. This application also provides a predictive model for the efficacy of neoadjuvant therapy in breast cancer, and a predictive model for the risk of recurrence and metastasis in breast cancer treated with neoadjuvant therapy. The constructed predictive model has a high AUC value (0.82-0.87), and good sensitivity and specificity. Furthermore, through regular postoperative monitoring, abnormal dynamic changes in immune cell subsets can be detected, potentially indicating signs of recurrence earlier than imaging and traditional tumor markers. This helps identify advantageous populations before treatment and high-risk populations after treatment, enabling optimization of treatment plans and individualized adjustment of follow-up density.

The invention discloses a magnetic nano-microsphere rapid separation and detection system for medical diagnosis of tumor markers, and relates to the technical field of medical diagnosis. The magnetic nano-microsphere rapid separation and detection system is prepared by the following steps: mixing serum of a patient with magnetic microspheres and carrying out constant-temperature pretreatment; applying an initial magnetic field to separate the microspheres, and synchronously collecting baseline data of a magnetoacoustic signal; constructing a dynamic function according to signals monitored in real time to guide a subsequent separation strategy; applying a self-adaptive alternating magnetic field, and selectively dissociating non-specifically adsorbed interferents; performing spatial enrichment on the target complex in a specific area by using a dynamic focusing magnetic field; and after fluorescence labeling and cleaning, correcting and calculating the final marker concentration in combination with whole-process signal data. By introducing the real-time feedback of the magnetoacoustic coupling signal and the dynamic magnetic field regulation and control strategy, the magnetic separation process can be actively sensed and optimized in a single detection period.

Provided is use of an endogenous micropeptide in cancer diagnosis or treatment. Particularly, the present invention relates to use of a micropeptide encoded on a long non-coding RNA as a tumor marker, a tumor treatment drug, and / or a tumor treatment target. Specifically, two micropeptides and variants thereof have been discovered for the first time. Moreover, provided are nucleotide sequences encoding the described micropeptides and recombinant vectors containing these nucleotide sequences, and also provided are use thereof in the preparation of a reagent or a drug for diagnosing, preventing, alleviating, or treating a tumor, and use of a drug or a reagent for an interfering micropeptide or a coding nucleic acid thereof in the preparation of a medicament or a pharmaceutical composition for preventing, alleviating, or treating a disease. The micropeptides not only provide biomarkers for the diagnosis of tumors, but also provide therapeutic drugs or therapeutic targets for the treatment of tumors.

The invention discloses application of METTL14 in inhibition of pituitary tumor cell proliferation and prognosis evaluation, and relates to the technical field of medicines. Experiments prove that when METTL14 is knocked out, E-cadherin can be lowered, and N-cadherin and waveform protein can be increased, so that the migration ability and proliferation and invasion ability of GH3 cells are promoted, and the tumor forming ability and in-vivo hormone level of pituitary growth hormone tumors are improved. Therefore, the METTL14 can be used for preparing a product for diagnosing or treating pituitary growth hormone adenoma, which is beneficial to theoretically researching pituitary adenoma and developing a novel targeted drug, and provides a new direction for finding a tumor marker or a new treatment strategy related to novel pituitary growth hormone adenoma diagnosis and controlling pituitary growth hormone adenoma.

The application relates to the technical field of biological medicine, and discloses a tumor marker micro-detection and analysis method based on liquid biopsy. The method comprises the following steps: extracting peripheral blood free DNA and performing double-end sequencing; jointly extracting multi-dimensional features such as ctDNA fragment length distribution, end sequence preference, nucleosome positioning signal and CpG methylation state from the sequencing data; constructing a feature matrix under unified genomic coordinates through space-time alignment; inputting a pre-trained cross-scale graph neural network model, taking a genomic region as a node and physical and functional proximity as an edge, learning a coupling mode of multi-modal features in a local chromatin structure, and outputting a malignant risk score; and combining a threshold to distinguish early lung cancer and benign and malignant nodules. The application comprises corresponding functional units and supports efficient parallel analysis. The system significantly improves detection sensitivity and specificity, reduces the false negative rate by 36%, and realizes non-invasive and accurate early lung cancer screening.

The embodiment of the application discloses a surgical field display method, device, equipment and medium, wherein the method comprises: acquiring a preset modality three-dimensional image and a three-dimensional ultrasound image of a preset region of interest, which displays preset tumor marker information; in response to an image fusion instruction, fusing the preset modality three-dimensional image and the three-dimensional ultrasound image to obtain an initial fusion effect image; in response to an image adjustment instruction of a user on the initial fusion effect image, adjusting the image display effect to obtain and display a target fusion effect image. The technical scheme of the embodiment of the application can display the surgical field intuitively and stereoscopically, so that the doctor can obtain more comprehensive and accurate structural morphological information and position information of the tumor, which is beneficial to assisting the doctor in positioning and diagnosing the lesion.

The invention discloses a method for detecting biomolecules, and relates to the technical field of micro-nano processing technology and LSPR biosensors. An existing LSPR sensor is low in sensitivity and large in spectral formant line width, and an existing MIM structure is complex in machining process, high in cost, tedious in modification step and insufficient in sensing performance stability. A metal-gap-metal composite structure is constructed, a pair of sensing chips is prepared, each sensing chip comprises a quartz substrate and an LSPR gold nanostructure array, a supporting structure is formed on the quartz substrate, buckling assembly is performed to accurately control the distance to form an MIM resonant cavity, and the active regulation and control of the electric field intensity are realized by combining biological modification and detection methods. The sensitivity of the sensor is remarkably improved, the spectral formant line width is reduced, the process is simplified, the cost is reduced, the stability is improved, and the sensor is used for detecting trace tumor marker antigens.

This invention discloses a method for identifying intrahepatic cholangiocarcinoma (ICC) based on serum peptide characteristics and its application. The invention collects serum samples from three groups: individuals with ICC, those with benign liver disease, and healthy controls. Peptide characteristic peaks associated with ICC are screened, and a model is constructed using a logistic regression algorithm. This model demonstrates excellent discriminative ability on both the training and independent test sets, with AUCs reaching 0.986 and 0.963, respectively, significantly outperforming traditional tumor markers CA19-9 and CEA. The peptide characteristic peak combination and the discriminative model constructed based on it can be used for early detection of ICC, differentiation between benign and malignant cases, and screening of high-risk populations. It offers advantages such as rapid detection, standardized procedures, strong early ICC identification capability, and low false positive rate, providing a highly sensitive, specific, and widely applicable non-invasive screening tool for clinical use.

The application discloses a chemiluminescence kit for detecting CA72-4 based on an acridinium ester system, which comprises magnetic microspheres connected with anti-CA72-4 monoclonal antibody mAb1, an acridinium ester label of anti-CA72-4 monoclonal antibody mAb2, CA72-4 antigen calibrators, a cleaning solution, an excitation solution and the like. The kit is simple to operate, the whole detection time is 20 min, the detection efficiency is greatly improved, the test precision is relatively high, and the CV is not higher than 5%. In addition, the test results of clinical samples show that the kit has a good clinical coincidence rate, and has important significance for the auxiliary diagnosis of various tumors.

The application belongs to the field of tumor molecular diagnosis and targeted therapy, and specifically finds lncRNA RP11-499F3.2 which is significantly highly expressed in head and neck cancer through bioinformatics analysis of TCGA data; it is verified through clinical samples that the expression level of RP11-499F3.2 in head and neck squamous cell carcinoma is significantly higher than that in paracancerous tissues, and is closely related to the clinical prognosis of patients with head and neck squamous cell carcinoma; it is found through functional experiments that high expression of RP11-499F3.2 can promote the in-vitro proliferation, migration and invasion of head and neck squamous cell carcinoma cells; meanwhile, it is also found that RP11-499F3.2 can promote the drug resistance of head and neck squamous cell carcinoma cells to cetuximab; the disclosed lncRNA RP11-499F3.2 helps to reveal the new pathogenesis of head and neck cancer, provides a new tumor marker for the prognosis monitoring of head and neck cancer, and provides a new idea for the clinical treatment of head and neck cancer.

The invention provides a living cell surface double-tumor marker in-situ detection method based on a closed bipolar electrode (cBPE) array and an electrochemiluminescence (ECL) technology. The living cell surface double-tumor marker in-situ detection method is used for synchronously quantifying carcino-embryonic antigen (CEA) and alpha-fetoprotein (AFP). According to the system, the high specific surface area, the ordered porous structure and the rich surface amino active sites of a covalent organic framework (COF) material are utilized, and the excellent conductivity and biocompatibility of gold nanoparticles (Au NPs) are combined, so that the bifunctional signal probe COF (at) Au (at) MBApt is constructed. The probe can simultaneously load a large number of signal molecule methylene blue (MB) and is coupled with a targeting aptamer (Apt), so that high-capacity labeling and specific recognition of a target marker are realized.

The invention discloses an immunochromatography test strip based on an asymmetric near-infrared driving nano motor and a preparation method and application thereof.The immunochromatography test strip comprises a bottom plate and a sample pad, filter paper, a nitrocellulose membrane and absorbent paper which are sequentially overlapped and pasted to the bottom plate, and when the immunochromatography test strip is used, a PZSA-Ab buffer solution is dropwise added to the surface of the sample pad; the PZSA (at) Ab buffer solution is prepared from a PS-SiO2 (at) Au nano composite material and an antibody to be marked; the PS-SiO2 (at) Au nano composite material is nanoparticles of an asymmetric snowman-shaped structure, polystyrene nanospheres are arranged at one end of the asymmetric snowman-shaped structure, hemispherical SiO2 nanoparticles are arranged at the other end of the asymmetric snowman-shaped structure, and Au nanoparticles are loaded on the surface of the asymmetric snowman-shaped structure. According to the present invention, the PS-SiO2 (at) Au nano-composite material is adopted as the nano-motor to be combined with the antibody to be labeled, and the near-infrared light is adopted to drive the snowman-shaped nano-motor to directionally move so as to achieve the active capture and enrichment of the tumor marker, such that the detection sensitivity and the detection speed of the immunochromatography test strip can be significantly improved.

The invention discloses an application of an improved isoluminol luminescent substrate in a MaglumiX8 chemiluminescence immunoassay system, and belongs to the technical field of in vitro diagnostic reagents. The luminescent substrate comprises an alkaline solution containing a metal leaf line complex and a derivative thereof, and a piperazine phenol derivative, and a peroxide solution containing urea and stannate. According to the invention, a metal leaf line substance is added into an alkaline solution, an active structure is stabilized through coordination modification, a reaction with hydrogen peroxide is promoted, a chemiluminescence signal is enhanced, and the luminous efficiency and the detection sensitivity are improved; by adding the piperazine phenol derivative, lasting glow of isoluminol is realized, signal stability is ensured, and result reliability is improved. In a hydrogen peroxide system, a urea / stannate stabilizer is added, so that the stability of a substrate is improved. Experimental verification shows that the substrate has high accuracy correlation with an original reagent, excellent precision and stable performance after being stored at room temperature for 24 months, and is suitable for the detection fields of hormones, tumor markers and the like.

The invention provides a digestive tract tumor course monitoring system. The system comprises a system control module, a first-stage detection module, a second-stage detection module, a third-stage detection module, a risk assessment module and an intervention decision module. The primary detection module is used for collecting tumor markers, images and clinical symptom data of a patient; the second-stage detection module is used for performing liquid biopsy, pathological biopsy and metabolic function evaluation on the first-stage positive patient; the third-stage detection module is used for carrying out micro-metastasis detection and immune microenvironment and genome analysis on a second-stage positive patient; the risk assessment module determines a patient risk level based on a detection result; the intervention decision module outputs intervention measures based on the risk level; the system control module manages and coordinates operation of all the modules. Each detection module automatically captures detection data by being connected with a hospital system, and judges an abnormal condition according to a set threshold value. According to the system, through a logic mechanism of grading detection and grading intervention, precise monitoring and early warning intervention on the disease course of the digestive tract tumor patient are realized.

The application relates to a preparation method and application of a ternary heterojunction composite photoelectrochemical immunosensor, and belongs to the technical field of photoelectrochemical biosensors, and particularly relates to a preparation method and application of a photoelectrochemical immunosensor for detecting alpha-fetoprotein by adopting a BiPO4 / BiOBr / CdS composite material. The method is characterized in that a ternary heterojunction is assembled on an FTO modified electrode to fix a capture antibody, and the accurate determination of alpha-fetoprotein is realized through a photocurrent signal response. The BiPO4 / BiOBr heterojunction expands the forbidden band width and expands the light absorption range; due to the sensitization of CDs, the absorption of visible light is enhanced, so that the photocurrent signal is increased. The method has the advantages of good stability, strong specificity, high sensitivity, good reproducibility and the like, is good for the rapid detection of alpha-fetoprotein, solves the existing technical difficulties, and provides a feasible method for the detection of tumor markers.